Alder BioPharmaceuticals Inc. (ALDR)’s Financial Results Comparing With Paratek Pharmaceuticals Inc. (NASDAQ:PRTK)

Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) and Paratek Pharmaceuticals Inc. (NASDAQ:PRTK), both competing one another are Biotechnology companies. We will contrast their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alder BioPharmaceuticals Inc. 12 0.00 N/A -4.78 0.00
Paratek Pharmaceuticals Inc. 5 5.62 N/A -3.76 0.00

Table 1 highlights Alder BioPharmaceuticals Inc. and Paratek Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.


Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Alder BioPharmaceuticals Inc. 0.00% -193.2% -67.2%
Paratek Pharmaceuticals Inc. 0.00% -232.6% -39.5%

Volatility and Risk

A beta of 2.49 shows that Alder BioPharmaceuticals Inc. is 149.00% more volatile than S&P 500. Competitively, Paratek Pharmaceuticals Inc.’s beta is 1.85 which is 85.00% more volatile than S&P 500.

Analyst Recommendations

The table delivered features the ratings and recommendations for Alder BioPharmaceuticals Inc. and Paratek Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Alder BioPharmaceuticals Inc. 0 0 1 3.00
Paratek Pharmaceuticals Inc. 0 0 1 3.00

Alder BioPharmaceuticals Inc.’s upside potential is 130.15% at a $20 average target price. Meanwhile, Paratek Pharmaceuticals Inc.’s average target price is $25, while its potential upside is 542.67%. Based on the analysts belief we can conclude, Paratek Pharmaceuticals Inc. is looking more favorable than Alder BioPharmaceuticals Inc.

Insider and Institutional Ownership

Institutional investors held 0% of Alder BioPharmaceuticals Inc. shares and 79% of Paratek Pharmaceuticals Inc. shares. Insiders held 0.1% of Alder BioPharmaceuticals Inc. shares. On the other hand, insiders held about 4.3% of Paratek Pharmaceuticals Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alder BioPharmaceuticals Inc. -4.44% -14.45% -18.65% -28.33% -43.62% -1.27%
Paratek Pharmaceuticals Inc. -3.87% -21.22% -40.41% -51.28% -67.54% -37.04%

For the past year Alder BioPharmaceuticals Inc. has stronger performance than Paratek Pharmaceuticals Inc.


On 5 of the 8 factors Paratek Pharmaceuticals Inc. beats Alder BioPharmaceuticals Inc.

Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. The companyÂ’s lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis. In addition, the company has preclinical programs in the discovery phase for various indications. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.